RT Journal Article
SR Electronic
T1 Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.10.20210070
DO 10.1101/2020.10.10.20210070
A1 Westerhuis, Brenda M.
A1 Aguilar-Bretones, Muriel
A1 Raadsen, Matthijs P.
A1 de Bruin, Erwin
A1 Okba, Nisreen M.A.
A1 Haagmans, Bart L.
A1 Langerak, Thomas
A1 Endeman, Henrik
A1 van den Akker, Johannes P.C.
A1 Gommers, Diederik A.M.P.J.
A1 van Gorp, Eric C.M.
A1 Rockx, Barry H.G.
A1 Koopmans, Marion P.G.
A1 van Nierop, Gijsbert P.
YR 2020
UL http://medrxiv.org/content/early/2020/10/12/2020.10.10.20210070.abstract
AB Severe acquired respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease (COVID-19). In severe COVID-19 cases, higher antibody titers against seasonal coronaviruses have been observed than in mild cases. To investigate antibody cross-reactivity as potential explanation for severe disease, we determined the kinetics, breadth, magnitude and level of cross-reactivity of IgG against SARS-CoV-2 and seasonal CoV nucleocapsid and spike from 17 severe COVID-19 cases at the clonal level. Although patients mounted a mostly type-specific SARS-CoV-2 response, B-cell clones directed against seasonal CoV dominated and strongly increased over time. Seasonal CoV IgG responses that did not neutralize SARS-CoV-2 were boosted well beyond detectable cross-reactivity, particularly for HCoV-OC43 spike. These findings support a back-boost of poorly protective coronavirus-specific antibodies in severe COVID-19 patients that may negatively impact de novo SARS-CoV-2 immunity, reminiscent of original antigenic sin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has received funding from the European Unions Horizon 2020 research and innovation program under grant agreements No. 874735 (VEO) and No. 101003589 (RECoVER) and the Netherlands Organisation for Health Research and Development (ZONMW) grant agreement 10150062010008.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were included in a biorepository study (MEC-2017-417) and samples were analyzed according to the SARS-CoV-2 protocol (MEC-2020-0222) with approval from the medical ethical committee of the Erasmus MC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available for review on request.